However, contrary to the accepted hypothesis that reduced serum adiponectin is associated with an increased CVD risk or CVD mortality in men, such a relationship has been reported to be reversed, particularly in elderly subjects, in patients with pre-existing CVD15, and in pre-dialysis CKD patients16. Here, ADIPOQ is linked to chronic kidney disease.